Two-and-a-half years ago in START-UP, Oxford Biosciences VC Doug Fambrough, PhD, divided the companies developing next-generation sequencing technologies into five categories: those who offered incremental improvements to the sequencing process; microfluidics specialists that could make front-end sample preparation more efficient; companies relying on PCR-based sequence amplification; companies attempting to sequence by base addition with little or no amplification; and firms attempting to read sequence "in real time" as strands of DNA passed through an apparatus. (See "Making a New, Big Splash in the Sequencing Market," START-UP, May 2004, Also see "Making a New, Big Splash in the Sequencing Market" - Scrip, 1 May, 2004..)
The categories still hold up today, Fambrough says, and understandably, certain fields have made progress while others haven’t. Attempts to read DNA in real time, for example, appear stalled, he...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?